Outcomes of trimodality CROSS regimen in older adults with locally advanced esophageal cancer

Abstract Background Chemoradiotherapy for Oesophageal cancer followed by Surgery (CROSS regimen) is standard of care for locally-advanced esophageal cancer. We evaluated CROSS completion rates, toxicity, and postoperative outcomes between older and younger adults receiving trimodality therapy. Methods Retrospective analysis of patients with locally-advanced esophageal cancer who underwent CROSS regimen from May 2016 to January 2020 at a single academic center. Outcomes of those aged ≥70-years-old and Results Of 201 patients, 136 were  0.05). Time to surgery following neoadjuvant therapy was similar between age groups, except in those ≥80-years-old as compared to  0.05). Conclusion Trimodality CROSS regimen for esophageal cancer in older adults is feasible, with similar completion rates and postoperative outcomes as compared to their younger counterparts.